Composition possessing adaptogenic, hepatoprotective and immunomodulatory action. RU patent 2473358.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and concerns an ergogenic formulation possessing adaptogenic, hepatoprotective and immunomodulatory action, and may be used in hepatic diseases, in decreases in immunity and increase in performance efficiency and tolerance. The composition contains burnut extract, zinc aspartate, magnesium aspartate, vitamin B6, water in certain proportions of the ingredients.

EFFECT: composition possess higher pharmacological activity and bioavailability.

3 ex

IPC classes for russian patent Composition possessing adaptogenic, hepatoprotective and immunomodulatory action. RU patent 2473358. (RU 2473358):

A61P37/02 - Immunomodulators

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K36/15 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

A61K31/4415 -

A61K31/194 -

Another patents in same IPC classes:

Pharmaceutical composition containing ahtm-cd6 monoclonal antibody, applicable for diagnosing and treating rheumatoid arthritis / 2472526
Group of inventions refers to medicine, namely immunology and may be used for treating rheumatoid arthritis. That is ensured by the use of a pharmaceutical composition containing an active principle presented by a monoclonal antibody which recognises a CD6 human leukocyte differentiation antigen and produced by secreting hybridoma IOR-TIA with deposition No. ECACC 96112640, and an applicable excipient. What is also presented is a method for the use of the pharmaceutical composition in the form of injections, as well as the use of a monoclonal antibody which recognises the CD6 human leukocyte differentiation antigen, for preparing a therapeutic agent.

Use of lactobacillus casei for intensified protection induced by influenza vaccination / 2470994
Bacterial Lactobacillus casei CNNM 1-1518 strain is used for preparing an oral composition for increasing humoral immunity induced in influenza vaccination, preferentially in patients aged 65 years and older. The composition is found in the form of an enzyme milk product, in the form of a foodstuff or a food additive, and with the content Lactobacillus casei CNNM 1-1518, preferentially 1x108 to 1x109 CFU/ml.

Immunomodulatory drug / 2470656
Invention refers to medicine, specifically pharmacology, and may be used for correction of immune disorders in pathological conditions associated with Th1-dependent type of immune response (chronic, smoldering and recurrent infectious, as well as oncological diseases).

Liquid formulations / 2470631
Present invention refers to medicine and describes a pharmaceutical concentration for dissolution before oral introduction, containing S1P receptor modulator or agonist specified in a group involving 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol, 2-amino-2-[4-(benzyloxyphenylthio)-2-chlorophenyl]ethyl-1,3-propanediol or proper phosphate, and 1-{4-[1-(4-cyclohexyl-3-trifluoromethylbenzyloxyimino)ethyl]-2-ethylbenzyl}azetidine-3-carboxylic acid, or their pharmaceutically acceptable salts, respectively, and 65 to 99 wt % propylene glycol, and optionally one or more other solvents, one or more aromatisers and/or one or more preserving agents; all the ingredients are added up to 100 wt %. What is also described is a pharmaceutical solution containing the concentrate, the use of the concentrate and the method for treating an individual in need of immune system suppression with the use of said concentrate.

Biologically active peptide complexes / 2470031
Invention relates to biologically active peptide complexes with immunomodulating and antiviral activity. The disclosed peptide complexes have a three-dimensional structure wherein X1 is absent or contains at least 1 amino acid; R1 and R2 are peptide chains which contain amino acid residues, His or Cys, capable of reacting with transition metal ions, wherein R1 contains up to 5 amino acid residues or is absent; R2 contains up to 3 amino acid residues or is absent.

Method of treating infectious-inflammatory complications of surgical operations in oral cavity with application of cytokine therapy / 2469736
Complex therapy, including introduction of antibiotics, is performed. Additionally carried out is immunomodulating therapy 2 ml of 0.2% superlimf during and for 5-7 days after operation 2 times per day.

Method of treating allergy, method of treating asthma, method of reducing risk of developing infection, and method of treating condition characterised by cytokine type 1 and 2 content imbalance by β-hydroxy-β-methylbutyrate / 2469719
For the purpose of treating allergy in an individual characterised by cytokine Th1 and Th2 imbalance, β-hydroxy-β-methylbutyrate (HMB) is introduced into the individual in an amount effective to reduce cytokine Th1 and Th2 production imbalance. What is also presented is a method of treating allergy in the individual belonging to a risk group of developing allergy.

Protein showing interferon-like antiviral and antiproliferative biological activities (versions), protein structure, coding polynucleotide (versions), expression vector, host cell, composition and use of protein as antiviral, antiproliferative, anticancer or immunomodulatory agent and method of treating condition sensitive to interferon-therapy, cancer or viral disease / 2469091
What is produced is a recombinant protein created by gene shuffling possessing higher antiviral and antiproliferative activities as compared with existing human interferon-alpha-2b (HulFN-α2b). The prepared polypeptide is used in a composition as an antiviral, antiproliferative, anticancer or immunomodulatory agent.

New synthetic tlr9 agonists / 2468819
Invention described immunomodulatory compounds of oligonucleotides individually providing unique profiles of cytokines and chemokines by relation as TLR agonists. The TLP9 agonists aim at modulation of immune responses mediated by Toll-like receptor (TLR). There are also described a composition containing an immunomodulatory compound and a physiologically acceptable carrier and enables producing an immune response in a patient, a method for producing the immune response in the patient with the use of the immunomodulatory compound, methods of therapeutic and preventive treatment in the patient in need of modulation of the immune response, particularly in cancer, autoimmune and inflammatory disorders, an infectious disease, allergy, asthma and other diseases. The immunomodulatory compounds may be used in a combination with other therapeutic agents and chemotherapeutic compounds used in specific diseases or disorders.

New application of il-1β compounds / 2468817
Presented group of inventions refers to medicine. What is presented is application of IL-1β binding antigen for producing a drug preparation for treating juvenile rheumatoid arthritis in a patient, containing at least one antigen-binding centre which involves a first domain having an amino acid sequence specified in SEQ ID NO:1, and a second domain having an amino acid sequence specified in SEQ ID NO:2. What is presented is a pharmaceutical composition containing said antibody in a combination with pharmaceutically acceptable excipients, solvents or carriers introduced parenterally.

Method of treating drug-induced liver injury in children suffering from tuberculosis / 2473346
Declared invention refers to medicine. The anti-tuberculosis preparations are cancelled, while Ursosal 20 mg/kg is single administered per os, and Enterosgel 10-15 g for 3 days. Then, a dose of Ursosan is reduced to 12-15 mg/kg a day with underlying reinitiation of the anti-tuberculosis preparations, and the Ursosan therapy is continued until the ALT value appears to be below an upper limit of normal.

Method of treating non-alcoholic fatty liver disease / 2473342
Invention relates to medicine, namely to gastroenterology and can be used for treatment of non-alcoholic fatty liver disease. For this purpose administered are metronidasol 250 mg 4 times per day, alpha-normix 200 mg 2 tablets x 2 times per day during 7-10 days.After that, treatment is performed with further administration of bifiform in dose 2 capsules in the morning, probifor in dose 25-30 doses 3 times per day, linex in dose 2 capsules 3 times per day, hylak forte 40-60 drops 3 times per day, sporobacterin 2-4 ml. Duration of intake constitutes 3-4 weeks, also administered is dufalak in dose 5-10 ml per day. Drug therapy of lipid metabolism disorders is performed in dependence of biochemical parameters: in case if ultrasonic signs of steatosis are present and level of transaminases is normal, statins in combination with ezetimibe are administered. If transaminases increase to 3 normal values, essential phospholipids are applied during 3 months. If transaminases increase higher than 3 normal values, ursodeoxycholic acid in dose 15-20 mg/kg is applied; if ultrasonic signs of non-alcoholic steato hepatitis are present and transaminases increase to 3 normal values, statins are administered in dose 20 mg and ursodeoxycholic acid in dose 15-20 mg/kg for 3-6 months. If transaminases increase higher than 3 normal values, treatment is performed with statins in dose 20-40 mg/day and ursodeoxycholic acid in dose 15-20 mg/kg, ezetimibe in dose 10 mg 1 time per day.

Method of preventing vertical transmission of hepatitis b and c viruses in pregnant women with reactivation of viruses in third trimester / 2473341
Invention relates to field of medicine, namely to infectious diseases and obstetrics, and can be used for prevention of vertical transmission of hepatitis B and C viruses in pregnant women. For this purpose in pregnant women with term of pregnancy from 28 to 30 weeks with reactivation of chronic viral hepatitis B and C, level of viral load is determined and if its value is higher than 105 copies/ml, preparation Kipferon is introduced in dose 2 suppositories 2 times per day rectally with 12 hour interval during 14 days, and starting from 36 weeks of pregnancy repeated course is carried out in accordance with the same scheme.

Method of treating non-alcoholic steatohepatitis with application of dalargin magnetophoresis / 2473325
Invention relates to medicine, gastroenterology. Method includes dietotherapy in accordance with diet No 5, exercise therapy. Additionally intake of low-mineralised carbonaceous chloride-hydrocarbonate-sulfate-sodium-calcium mineral water "Essentuki-Novaya" is realised. Water is taken in in dose 3.5 ml per 1 kg of patient's body weight, 3 times per day, 30-40 minutes before meal. Carbonaceous-hydrogen sulfide mineral baths with content of hydrogen sulfide 15-20 mg/l are carried out every second day. Baths are taken with water temperature 36-37°C. Course includes 8-10 procedures. Dalargin magnetophoresis on liver projection is performed daily. Pulsing travelling magnetic field from apparatus AMO-ATOS is used. Magnetophoresis is carried out with induction 45 mT, with modulation frequency 10 Hz for 15 minutes, course includes 10 procedures.

Agent normalising liver mitochondria / 2470655
Invention refers to medicine, more specifically pharmacology. Grape seed extract is presented as an agent normalising liver mitochondria.

Agent possessing antiarrhythmic and hepatoprotective properties / 2469720
Invention refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide of formula I: as an agent possessing antiarrhythmic and hepatoprotective properties. The invention also refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide for preparing pharmaceutical compositions.

Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition / 2468803
There are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.

Method of preventing chronic toxic hepatopathy / 2468446
In order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Liquid composition improving working performance and possessing adaptogenic, wound-healing and anti-inflammatory action / 2473357
Invention refers to pharmacy and concerns formulations possessing adaptogenic, anti-inflammatory and working performance improving action, and are applicable for treating gastrointestinal diseases (gastritis, gastric ulcer) and for body adaptation to the adverse conditions and improving working performance. The composition contains royal jelly, purified propolis and additionally fructose and glucose syrups, pollen extract, vitamin E, preserving agent, sweetener and water in specific proportions.